Contrast-Induced Acute Kidney Injury

Pathophysiology and Clinical Presentation

Contrast-induced acute kidney injury (CI-AKI) is an intrinsic renal process involving direct tubular toxicity, renal medullary ischemia, and cellular damage from reactive oxygen species, as supported by the European Heart Journal 1
The pathogenesis of CI-AKI is multifactorial, involving direct tubular toxicity via reactive oxygen species, renal medullary ischemia, direct cellular toxicity from the contrast agent, and decrease in glomerular filtration and renal hypoperfusion, according to the European Heart Journal 1
CI-AKI presents with a defined rise of serum creatinine of 44 mmol/L (0.5 mg/dL) or a 25% relative rise from baseline at 48 hours (or 5-10% at 12 hours) following contrast administration, as stated in the European Heart Journal 1
The American Journal of Kidney Diseases notes that pre-existing impaired renal function is the principal risk factor for CI-AKI, with patients having serum creatinine >2 mg/dL at a nearly 10-fold increased risk 2

The American Journal of Kidney Diseases identifies diabetes mellitus, especially when combined with renal impairment, heart failure, repeated contrast exposure over short periods, and concomitant nephrotoxin administration as risk factors for CI-AKI 2
The European Heart Journal recommends intravenous volume expansion with isotonic sodium chloride or sodium bicarbonate as the most effective method of reducing CI-AKI risk, as well as using the lowest possible dose of contrast medium and iso-osmolar or low-osmolar iodinated contrast media 1
The American Journal of Kidney Diseases suggests considering N-acetylcysteine together with IV isotonic crystalloids in high-risk patients, though evidence for benefit remains inconclusive, and calculating contrast volume to creatinine clearance ratio to minimize risk 2, 3

The American Journal of Kidney Diseases notes that most episodes of CI-AKI are nonoliguric, and the majority of contrast-enhanced procedures are performed in outpatient settings where urine output monitoring is impractical 2
The European Heart Journal states that loop diuretics are not recommended for prevention or treatment of CI-AKI, and prophylactic intermittent hemodialysis or hemofiltration is not recommended for contrast media removal in at-risk patients 1, 3
Kidney International suggests that the risks associated with IV contrast are lower than previously thought, particularly in patients with normal or mildly reduced baseline kidney function, and IV contrast should not be withheld due to AKI concerns in life-threatening conditions 4

The Kidney International guidelines suggest that CI-AKI is defined as a rise in serum creatinine, with a systematic review demonstrating similar risks of AKI, dialysis initiation, and mortality between enhanced and unenhanced CT 5

The American College of Radiology and other societies acknowledge that recent evidence has questioned whether contrast media directly causes kidney injury in many cases, with multiple propensity score-matched analyses of over 60,000 patients showing no significantly enhanced AKI risk with contrast-enhanced versus unenhanced CT 5
Patients with pre-existing kidney disease have a higher risk of CI-AKI, with a prevalence of 9% in cancer patients, while those without kidney disease have a lower risk of approximately 5% 5
The National Kidney Foundation and other organizations recognize that patients with CKD G4-G5 remain at highest risk, with a 13.6% incidence of CI-AKI 5